My fellow IPIX shareholders,
I’d like to take a moment to share with you an extremely interesting article published on September 18, 2020, in The New Yorker, which speaks to our excitement in developing Brilacidin, our flagship defensin mimetic.
The article, “Scientists Advance on One of Technology’s Holy Grails,” goes into extensive detail regarding the accelerating trend in designing proteins for treating notoriously difficult maladies, including COVID-19 and cancer, in addition to other non-medical applications. William DeGrado, who recently joined the Company as a Scientific Advisor, is cited given his seminal work in this area. The crux of the article is the importance of, and opportunity in developing, novel therapies by designing and manufacturing variations of innate proteins to fill gaps in medicine today, and potentially to do so more efficiently than current drug discovery efforts.
Brilacidin is designed to mimic human proteins that serve as the front line of defense for the immune system. As we have theorized since our acquisition of Brilacidin – and subsequently supported by successful results in clinical trials in supportive cancer care, bacterial infections, and inflammatory bowel disease – the drug has exhibited robust therapeutic properties, with platform potential across numerous indications.
I encourage all our shareholders to read the highly informative article available at https://www.newyorker.com/tech/annals-of-technology/the-promise-of-designer-protein-in-the-fight-against-covid-19